A six-year proof-of-concept study published this week has demonstrated, for the first time, that sperm production in mice can be completely and safely halted — then fully restored — using a targeted small-molecule compound, bringing researchers closer to a long-sought goal in reproductive medicine.
The study, led by Paula Cohen, professor of genetics and director of the Cornell Reproductive Sciences Center, was published April 7 in the Proceedings of the National Academy of Sciences. The research was supported by the Gates Foundation and represents a significant step toward giving men a meaningful, nonhormonal option in contraception — an area that has seen very little progress for decades.
Why Male Contraception Has Stalled
For most of modern medicine’s history, male contraceptive options have remained fixed at two: condoms and vasectomies. Researchers have been especially reluctant to develop a hormonal contraceptive, as such treatments have proven potentially dangerous in women. “So we were really motivated to look for nonhormonal contraceptive targets in the testis, something that stops sperm production without affecting male libido and secondary sex characteristics,” said Cohen.
Those secondary sex characteristics — facial and chest hair, a deep voice, muscle mass — are regulated by hormones, not sperm production. Targeting the hormonal system to prevent fertility risks disrupting all of them. The Cornell team’s approach sidesteps that problem entirely by working directly on the biology of sperm development itself.
The Science: Targeting Meiosis at the Right Moment
Meiosis represents a natural checkpoint in sperm production where transient inhibition could achieve precise and reversible fertility control. Sperm production moves through three stages: it begins with stem cells, proceeds through meiosis — the process by which cells divide and differentiate into sperm precursors — and concludes with spermiogenesis, the final maturation phase.
Cohen and colleagues decided to target meiosis, as opposed to other stages, in order to fully stop sperm production in a manner that was reversible and that left males otherwise fully functional. “We didn’t want to impact the spermatogonial stem cells, because if you kill those, a man will never become fertile again,” Cohen said. Also, once sperm entered spermiogenesis, there was a potential for viable sperm to leak out and fertilize an egg.
The window they identified — a stage of meiosis called prophase 1 — proved to be the precise point where intervention could be both effective and reversible.
How JQ1 Works
To achieve this, scientists used JQ1, a small molecule inhibitor originally developed to study cancer and inflammatory diseases. While JQ1 is not suitable as a treatment due to neurological side effects, it is known to interfere with a stage of meiosis called prophase 1. This allowed researchers to demonstrate, for the first time, that targeting meiosis can safely and reversibly shut down sperm production.
JQ1 disrupts meiosis by killing cells during a stage called prophase 1, and it cuts off the onset of gene expression required for spermiogenesis. In the study, the researchers administered JQ1 in male mice for three weeks. They found that the mice produced no sperm, and that all the molecular parameters of meiosis were disrupted, including chromosomal behavior during prophase 1.
The result was complete contraceptive efficacy during treatment — with no sperm detected in any treated mouse.
Full Recovery — and Healthy Offspring
The critical test was not whether JQ1 could stop sperm production, but whether fertility could return once treatment ended.
Then they stopped delivering JQ1, and within six weeks, most of the healthy parameters of prophase 1 returned, along with normal sperm production. The team then bred those mice and confirmed they were fertile. They also bred the pups — the offspring of post-treatment mice — and confirmed that the second generation was healthy as well, ruling out heritable effects from the compound.
“Our study shows that mostly we recover normal meiosis and complete sperm function, and more importantly, that the offspring are completely normal,” said Cohen.
That multi-generational confirmation is an important detail. It demonstrates that JQ1’s interference with meiosis did not introduce genetic errors that persisted beyond the treated animals — a key requirement for any future contraceptive candidate.
What Comes Next: Three New Targets and a Company
JQ1 itself is not the end product. Its neurological side effects make it unsuitable for human use, and the Cornell team has always treated it as a proof-of-concept tool rather than a drug candidate. What the six-year study accomplished was to confirm that the underlying biological approach — targeting meiotic prophase 1 — is sound.
Moving forward, Cohen is considering new targets in meiosis that disrupt the process earlier, just at the entry into prophase 1, which would further ensure that no sperm survive. Targeting an earlier phase in the process would also improve drug delivery, due to the development of the blood testes barrier, which protects later stages of sperm development.
The team is working towards testing three new gene targets. “We have three targets that when knocked out, we know they absolutely obliterate meiosis and the mice have no sperm, and functionally and biologically, those mice are very healthy,” Cohen said.
If developed for human use, this type of male contraceptive could be delivered as an injection given every three months or possibly as a patch to maintain effectiveness. Cohen and colleagues have also announced plans to launch a company within the next two years to move these methods closer to clinical application.
A Shift in Reproductive Health Equity
The broader context matters here. For decades, the burden of contraception has fallen almost entirely on women — who must navigate hormonal side effects, intrauterine devices, implants, and surgical options. Male participation has been structurally limited by the absence of viable alternatives beyond condoms.
By coupling temporal molecular precision with comprehensive recovery genomic profiling, this work provides a framework for developing meiosis-based male contraceptives that are both effective and inherently reversible, advancing the field toward practical, equitable solutions for fertility control.
The Cornell study does not deliver a market-ready contraceptive — significant work remains before human trials can begin. But it does something arguably more important at this stage: it establishes that the biological target is valid, the mechanism is reversible, and the next generation is unaffected. That is a scientific foundation that researchers can now build on.
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice. The research described is a preclinical study conducted in mice and has not been tested in humans. Readers should consult a qualified healthcare professional for guidance on reproductive health and contraceptive options.
